CAR-T cell therapy
CAR-T is an approved treatment for specific blood cancers, with benefit that may last and serious risks. The FDA has eased some restrictions on treatment centres, but boxed warnings and long-term follow-up remain. That does not make all cancers curable, and the next thing to watch is how many eligible patients can be treated safely.
Research snapshot · updated Nov 12, 2026
Core thesis
CAR-T (chimeric antigen receptor T-cell therapy) engineers a patient's own immune cells to attack cancer. Novartis Kymriah and Gilead Yescarta approved for blood cancers. Complete remission rates of 40-60%. But: $400K+ per treatment, weeks of manufacturing per patient, and severe side effects (cytokine release syndrome). The next frontier: allogeneic (off-the-shelf) CAR-T that doesn't require patient-specific manufacturing.
State of the art (2026)
The FDA approved Aucatzyl on 8 November 2024, adding it to the earlier CAR-T products Kymriah, Yescarta, Tecartus, Breyanzi, Abecma and Carvykti. All are made from the patient's own cells and all treat blood cancers. In multiple myeloma the two approved products have different rules. Carvykti can be given after at least one earlier line of treatment, to patients whose disease no longer responds to lenalidomide. Abecma can be given after two or more earlier lines that included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. The FDA has eased some restrictions on treatment centres, but boxed warnings and long-term follow-up remain.
Explore the deeper analysis in CanaryIQ
Explore what is covered below. These previews show the structure; log in to read the full analysis.
Signal stack
Evidence stacked leading → lagging
9 signals
Signal stack
Evidence stacked leading → lagging
Technology-native KPIs
Metrics that predict trajectory, tracked over time
3 tracked
Technology-native KPIs
Metrics that predict trajectory, tracked over time
Landscape map
Who builds what, and who depends on whom
59 players · 6 layers
Landscape map
Who builds what, and who depends on whom
Catalyst calendar
Dated events that will move the position
4 ahead
Catalyst calendar
Dated events that will move the position
Technology roadmap
Milestones on the path to maturity
8 milestones
Technology roadmap
Milestones on the path to maturity
Watchlists
Companies, people and papers, each with a condition for removing it
20 · 19
Watchlists
Companies, people and papers, each with a condition for removing it
Decision frameworks
What our view means for your job
Locked
Decision frameworks
What our view means for your job
Thesis changelog
When our view changed, and why
8 updates
Thesis changelog
When our view changed, and why
Change our mind
3 disconfirming conditions
You've read the verdict. The file is much deeper.
The full signal stack, technology-native KPIs tracked over time, the landscape of who depends on whom, the dated catalyst calendar, decision frameworks for every desk, live watchlists and a record of every time our view on CAR-T cell therapy has changed. All of it is in CanaryIQ.